source
- Scynexis secures $200M+ BARDA contract for investigational antifungal SCY-247Scynexis announced a partnership with the U.S. Biomedical Advanced Research and Development Authority (BARDA) that provides more than $200 million to advance SCY-247, an experimental therapy aimed…
- Merck and Daiichi withdraw FDA accelerated approval filing for B7-H3 ADC in small cell lung cancerMerck and Daiichi Sankyo announced they have withdrawn their joint FDA accelerated approval filing for a B7-H3 antibody-drug conjugate intended for a subset of small cell lung cancer patients. The…